Do metallothioneins affect the response to treatment in testis cancers?

Journal of Cancer Research and Clinical Oncology

Volumn 124, Issue 1, 1998, Pages 31-36

  Eid, Hanna ^a   Géczi, Lajos ^a   Bodrogi, István ^a   Institoris, Etel ^a   Bak, Mihály ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Immunohistochemistry; Metallothionein; Response to treatment; Testicular germ cell tumors

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METALLOTHIONEIN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; SEMINOMA; TESTIS CANCER;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METALLOTHIONEIN; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 0031883364     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050130     Document Type: Article

References (30)

1. Angel P, Poting A, Nallick U, Rahmsdorf HJ, Schorrp M, Herrlich P (1986) Induction of metallothionein and other mRNA species by carcinogens and tumour promoters in human primary skin fibroblasts. Mol Cell Biol 6:1760-1766
2. Cattoretti G, Becker GM, Key G, Duchrow M, Schlüter C, Gall J, Gerd J (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357-363
3. Chin JL, Banerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ, Cherian MG (1993) Metallothionein in testicular germ cell tumors and drug resistance. Cancer 72:3029-3035
4. Eid H, Van der Looij M, Institoris E, Géczi E, Bodrogi I, Olá h E, Bak M (1997) Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer. Anticancer Res 17:2663-2670
5. Fritsche M, Haessler C, Brander G (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agent. Oncogene 8:307-318
6. Hall PA, Lane DP (1994) p53 in tumour pathology: can we trust immunohistochemistry? Revisited! J Pathol 172:1-4
7. Hamer DH (1986) Metallothionein. Annu Rev Biochem 55:913-951
8. International Union Against Cancer (UICC) (1987) TNM classification of malignant tumours. 4th edn. Springer, New York Berlin Heidelberg
9. Jasani B, Anstey A, Marks R, Long C, Pearse A (1993) Wild type p53 and metallothionein are expressed simultaneously in UV irradiated skin: a possible link to photocarcinogenesis (abstract). J Invest Dermotol 101:422
10. Javapour N (1980) The role of biologic tumor markers in testicular cancer. Cancer 45:[Suppl]1755-1761
11. Kaina B, Lohrer H, Karin M, Herrlich P (1990) Overexpressed human metallothionein IIA gene protects Chinese hamster ovary cells from killing by alkylating agents. Proc Natl Acad Sci USA 87:2710-2714
12. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazzo JS (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813-1815
13. Kontozoglou TE, Banerjee D, Cherian MGG (1989) Immunohistochemical localization of metallothionein in human testicular embryonal adenocarcinoma. Virchows Arch [A] 45:545-549
14. Lambkin HA, Mothersill CM, Kelehan P (1994) Variations in Immunohistochemical detection of p53 protein over-expression in cervical tumours with different antibodies and methods of detection. J Pathol 172:13-18
15. Leyshon-Sorland K, Morkrid L, Rugstad HE (1993) Metallothionein: a protein conferring resistance in vitro to tumor necrosis factor. Cancer Res 53:4874-4880
16. Lipponen PK (1993) Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 53:465-470
17. Li T-Y, Kraker AJ, Shaw CF, Petering DH (1980) Ligand substitution reactions of metallothioneins with EDTA and apocarbonic anhydrase. Proc Natl Acad Sci USA 77:6334-6338
18. Monfardini S, Brunner K, Crowther D, Olive D, MacDonald J, Eckhardt S, Whitehouse J, Reed D (1981) Manual of cancer chemotherapy, 3rd edn. UICC Technical Report Series 56:Geneva
19. Mostofi FK, Sesterhenn IA, Davis CJ (1986) World health organisation international histological classification of germ-cell tumours of the testis. In: Jones WG, Ward MA, Anderson CK (eds), Germ-cell tumours. II. Pergamon, Oxford, pp 1-23
20. Murphy D, McGown AT, Crowther D, Mander A, Fox BW (1991) Metallothionein levels in ovarian tumours before and after chemotherapy. Br J Cancer 63:711-714
21. Murphy BJ, Ladeonite KR, Chin RJ, sutherland RM (1994) metallothionein. IIA up regulated by hypoxia in human A 431 squamous carcinoma cells Cancer Res 54:5808-5810
22. Peckham MJ (1979) An appraisal of the role of radiation therapy in the managment of nonseminomatous germ-cell tumors of the testis in the era of effective chemotherapy. Cancer Treat Rep 63:1653-1658
23. Renan MJ, Dowman PI (1989) Increased radioresistance of tumour cells exposed to metallothionem-inducing agents. Radiat Res 120:442-455
24. Robson T, Hall A, Lohrer H (1992) Increased sensitivity of a Chinese hamster ovary cell line to alkylating agents after overexpression of the human metallothionein II-A gene. Mutat Res 274:177-185
25. Sadhu C, Gredamu L (1988) Regulation of human metallothionein (MT) genes. J Biol Chem 263:2679-2684
26. Schilder RJ, Half L, Monks A, Handel LM, Fornace AJ, Ozols RF, Fojo AT, Hamilton TC (1990) Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 45:416-422
27. Sugano T, Nitta M, Ohmori H, Yamaizumi M (1995) Nuclear accumulation of p53 in normal human fibroblasts is induced by various cellular stresses which evoke the heat shock response, independently of the cell cycle. Jpn J Cancer Res 86:415-418
28. Webber MM, Rehman SMM, James GT (1988) Metallothionein induction and deinduction in human prostatic carcinoma cells: relationship with resistance and sensitivity to adriamycin. Cancer Res 48:4503-4508
29. Williams DS, Birch R, Einhorn HL, Irwin L, Greco FA, Loehrer JP (1987) Treatment of disseminated germ-cell tumors with cisplatin, Bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1453-1440
30. Zeng J, Heuchel R, Schaffner W, Kagi JH (1991) Thionein (apometallothionein) can modulate DNA binding and transcription activation by zinc linger containing factor Spl. FEBS Lett 279:310-312